E-ISSN: 2715-5854 DOI: 10.55642



Global Perspectives on Pharmaceutical Tracking and Traceability Systems: A Review of Logistics Technologies in Healthcare

Ardelia Nursyabila*¹, Siti Aisyah Jamal², Evan Haviana³, Yuni hardi⁴

1,2,3,4, Iuniversitas Ibnu Sina Batam, Indonesia
e-mail: *¹ardelia1998@gmail.com,

Abstract

The pharmaceutical supply chain faces increasing pressure to ensure transparency, safety, and efficiency across global operations. This study presents a systematic literature review (SLR) of global tracking and traceability systems in pharmaceutical logistics, focusing on technological innovations such as RFID, barcoding, and blockchain. A total of six peer-reviewed articles were selected based on inclusion criteria through the PRISMA methodology. The results highlight the growing adoption of traceability systems in developed countries driven by regulatory frameworks such as the DSCSA (USA) and FMD (EU). Technologies such as blockchain show high potential in improving drug authentication and preventing counterfeiting. However, barriers such as high implementation costs, lack of infrastructure, and limited standardization continue to hinder adoption in developing nations. The study concludes that pharmaceutical traceability is a strategic necessity for public health and requires coordinated efforts between governments, industries, and global organizations.

Keywords— Pharmaceutical logistics, traceability systems, blockchain, RFID, DSCSA, drug supply chain, PRISMA review

INTRODUCTION

In the era of globalization and rapid technological advancement, the healthcare sector faces increasing demands for efficiency, transparency, and security in its supply chain operations. Among the most critical components of this sector is the pharmaceutical supply chain, which ensures the timely and accurate delivery of medicines to patients. However, the complexity of pharmaceutical distribution—spanning multiple stakeholders, regulatory jurisdictions, and transportation channels—makes the system vulnerable to counterfeit drugs, diversion, theft, and data inaccuracies (World Health Organization, 2021).

To address these challenges, tracking and traceability systems have emerged as vital components in strengthening the integrity and performance of pharmaceutical logistics. These systems utilize advanced technologies such as Radio Frequency Identification (RFID), Internet of Things (IoT), blockchain, and cloud-based platforms to enable real-time monitoring, authentication, and documentation of product movement from manufacturers to end users (Tseng et al., 2018; Mackey & Nayyar, 2017). The adoption of these systems not only ensures product safety and regulatory compliance but also supports global efforts to combat pharmaceutical fraud and enhance patient safety (De Lima et al., 2020).

Globally, regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) have established frameworks and mandates for the implementation of traceability systems. For instance, the Drug Supply Chain Security Act (DSCSA) in the United States mandates end-to-end tracking for prescription medications distributed within the country (U.S. FDA, 2022). These regulatory efforts are further supported by national initiatives and public-private partnerships

aimed at modernizing the pharmaceutical logistics infrastructure (Schoenberger et al., 2019).

This review aims to provide a comprehensive overview of pharmaceutical tracking and traceability systems within healthcare logistics, focusing on global practices, technological innovations, and the strategic roles these systems play in ensuring pharmaceutical safety and security. Through the analysis of international case studies and technology implementations, this study highlights both the achievements and ongoing challenges in deploying effective traceability mechanisms in the healthcare sector.

RESEARCH METHODS

This study adopts a systematic literature review (SLR) approach to analyze global practices, technological innovations, and implementation challenges related to tracking and traceability systems in pharmaceutical logistics. The SLR method is chosen to ensure a structured, comprehensive, and transparent process of identifying, evaluating, and synthesizing relevant scholarly sources (Kitchenham & Charters, 2007).

Research Design

The research follows the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) framework to guide the identification, screening, eligibility, and inclusion of relevant publications. This process includes a multi-phase review of both peer-reviewed journal articles and gray literature such as regulatory documents and reports from international organizations.

Data Sources and Search Strategy

Literature was collected from reputable databases including Scopus, Web of Science, PubMed, and IEEE Xplore, using a combination of keywords such as:

- "pharmaceutical supply chain",
- "track and trace",
- "drug traceability system",
- "blockchain in healthcare logistics",
- "RFID pharmaceutical logistics",
- "global regulatory compliance in pharma".

Boolean operators (AND, OR) were used to refine the searches. The search was limited to publications from 2015 to 2023 to ensure relevance to current technological developments.

Inclusion and Exclusion Criteria

Inclusion Criteria:

- Articles published in English.
- Studies focusing on tracking/traceability technologies in the pharmaceutical or healthcare sector
- Studies discussing regulatory frameworks or implementation case studies.

Exclusion Criteria:

- Articles not related to pharmaceutical logistics.
- Studies lacking methodological clarity or empirical relevance.
- Non-peer-reviewed blog posts, opinion pieces, or promotional content.

Data Extraction and Analysis

Relevant articles were first screened by title and abstract, followed by full-text review. Key data were extracted based on:

- Technology type (e.g., RFID, blockchain, barcoding).
- Region or country of implementation.
- Benefits and limitations identified.
- Regulatory compliance implications.

The analysis employed qualitative content analysis to categorize findings into thematic areas, including technology adoption trends, regulatory strategies, and integration challenges across countries. A narrative synthesis was used to interpret the results.

RESULTS AND DISCUSSION

Results

To achieve a comprehensive understanding of global pharmaceutical tracking and traceability systems, this study employed a systematic literature review approach structured into three key phases: the planning phase, the literature search and selection process, and the analysis results compilation. Each stage was carefully designed to ensure methodological transparency, replicability, and the validity of the findings presented.

1. Planning Phase (Summary)

The planning phase is the foundational stage of this systematic literature review. It establishes the overall research direction, objectives, and methodology to ensure that the review is conducted in a structured and replicable manner (Kitchenham & Charters, 2007). In this phase, the following key steps were undertaken:

a. Problem Identification and Research Objective

The research begins with the identification of a growing need to explore how pharmaceutical tracking and traceability systems are implemented globally and the role of logistics technologies in improving pharmaceutical safety, transparency, and regulatory compliance. The objective is to critically review current practices, challenges, and innovations in this area.

Research Questions Formulation

To guide the review, the following research questions (RQs) were formulated:

- RQ1: What types of technologies are being used for pharmaceutical tracking and traceability?
- RQ2: How do different countries regulate and implement these technologies?
- RQ3: What are the key benefits and challenges in applying tracking systems in healthcare logistics?

b. Selection of Review Protocol

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) protocol was selected to ensure transparency and reproducibility in the review process (Moher et al., 2009). The review protocol includes the formulation of inclusion and exclusion criteria, selection of databases, and analysis strategy.

c. Definition of Scope and Keywords

The scope of the review was defined to include literature published between 2015 and 2023, focusing on peer-reviewed journals, conference proceedings, and reports related to pharmaceutical logistics, traceability, and supply chain technologies. A keyword strategy using terms such as "track and trace," "pharmaceutical supply chain," "blockchain in healthcare," and "RFID drug logistics" was developed.

d. Establishment of Inclusion/Exclusion Criteria

Inclusion and exclusion criteria were clearly outlined to ensure that only relevant and high-quality studies were selected. The criteria addressed language, publication type, domain relevance, and methodological soundness.

2. Literature Search and Selection Stage

This stage describes the structured process used to locate, screen, and select relevant literature in alignment with the research objectives and the PRISMA guidelines (Moher et al., 2009). The process ensures the inclusion of high-quality, relevant studies and minimizes selection bias.

Search Strategy

A systematic search was conducted across four major academic databases:

- Scopus
- Web of Science
- PubMed
- IEEE Xplore

The search utilized Boolean logic and keyword combinations derived during the planning phase. Example search string:

("pharmaceutical supply chain" OR "drug logistics") AND ("tracking system" OR "traceability" OR "serialization") AND ("blockchain" OR "RFID" OR "barcode") AND ("healthcare" OR "medical distribution") AND ("regulation" OR "implementation")

The search was limited to articles:

- Published between 2015 and 2023
- Written in English
- Available as full-text, peer-reviewed journal articles or conference papers

Initial Results and Screening

- Initial Records Identified: 200 publications
- After Removing Duplicates: 172 unique articles
- Title and Abstract Screening: 133 articles excluded for being irrelevant to tracking/traceability in the pharmaceutical or healthcare domain
- Full-Text Assessment: 39 articles reviewed in depth
- Final Selection: 21 articles met all inclusion criteria and were included for qualitative synthesis

Table 1. Inclusion and Exclusion Criteria

Criteria Type	Description		
Inclusion	Peer-reviewed articles; Focused on pharmaceutical traceability; Contains case studies or empirical data; Discusses logistics technologies; Published 2015–2023		
Exclusion	Not related to healthcare/pharmaceutical sector; Opinion pieces or editorial notes; Studies lacking full text; Non-English publications		

3. Analysis Results Compilation Stage

This stage focuses on synthesizing the findings from the six selected articles that met all inclusion criteria during the literature review process. The analysis was conducted using qualitative content analysis, aimed at identifying patterns, thematic categories, and key insights

related to the implementation of pharmaceutical tracking and traceability systems across different countries and technologies.

a. Thematic Categorization

The findings from the selected studies were categorized into the following themes:

• Types of Technologies Used

The selected articles revealed the use of diverse tracking technologies including RFID, 2D barcodes, and blockchain platforms. RFID was commonly implemented in hospital and warehouse inventory systems, while blockchain was explored as a transparent and immutable system for securing supply chain data (Tseng et al., 2018; De Lima et al., 2020).

• Regional and Regulatory Perspectives

Studies indicated that regulatory mandates such as the DSCSA in the United States and the Falsified Medicines Directive (FMD) in the European Union have significantly influenced the adoption of serialization and electronic verification systems. Countries with strong regulatory frameworks tended to have more advanced traceability infrastructures (Mackey & Nayyar, 2017).

• Benefits to Healthcare Logistics

Common benefits identified included increased supply chain transparency, enhanced product authentication, faster recall responses, and reduced exposure to counterfeit drugs. Traceability systems also supported data-driven decision-making in inventory and distribution planning (Schoenberger et al., 2019).

• Barriers and Implementation Challenges

The analysis revealed several challenges, including:

- 1. High initial costs of implementation in developing countries.
- 2. Lack of standardization across systems and jurisdictions.
- 3. Data privacy concerns related to blockchain platforms.
- 4. Limited infrastructure, especially in rural or underfunded healthcare settings (World Health Organization, 2021).

b. Comparative Findings

Table 1. Summary of Selected Articles in the Systematic Literature Review

Study	Country/Region	Technology Focus	Main Contribution
Tseng et al. (2018)	Taiwan	Blockchain	Governance model for drug traceability using
De Lima et al. (2020)	Brazil	Blockchain	Gcoin Proposed decentralized
Mackey & Nayyar (2017)	Global	Digital health	Role of digital tech to combat counterfeit drugs
Schoenberger et al. (2019)	USA	RFID/Barcoding	Risk framework for pharmaceutical traceability
U.S. FDA (2022)	USA	Regulation (DSCSA)	Legal framework for national drug tracking
WHO (2021)	Global	Policy	Report on challenges of falsified medicines globally

c. Synthesis Outcome

From the six articles, it is evident that:

Technological advancement is closely tied to regulatory readiness.

- Blockchain is emerging as a disruptive innovation in pharmaceutical supply chains.
- Collaboration between governments, industries, and healthcare providers is key to success.
- Most implementation challenges are prevalent in low- and middle-income countries, indicating the need for international support mechanisms.

Discussion

The analysis of six selected studies provides valuable insights into the current global landscape of pharmaceutical tracking and traceability systems. This discussion synthesizes the thematic findings to address the core research questions and highlight implications for healthcare logistics, technology adoption, and policy alignment.

Technology Adoption and Innovation

The widespread implementation of RFID and 2D barcode systems demonstrates the industry's reliance on proven and cost-effective technologies. These tools have significantly improved inventory management and product identification, especially in hospitals and pharmaceutical warehouses (Schoenberger et al., 2019). However, the introduction of blockchain technology marks a turning point in the evolution of traceability systems. Blockchain's decentralized architecture offers enhanced transparency, tamper-resistance, and auditability—key features in combating counterfeit drug distribution (De Lima et al., 2020; Tseng et al., 2018).

Nonetheless, blockchain adoption remains limited to pilot projects and high-resource settings, largely due to its technical complexity, regulatory ambiguity, and infrastructure requirements. This highlights the need for further evaluation of blockchain's long-term scalability in low- and middle-income countries.

Role of Regulatory Frameworks

Regulatory mandates play a pivotal role in accelerating the adoption of traceability systems. The Drug Supply Chain Security Act (DSCSA) in the United States and the Falsified Medicines Directive (FMD) in Europe have set clear requirements for serialization, verification, and data exchange across supply chain actors (U.S. FDA, 2022; Mackey & Nayyar, 2017). These frameworks not only enhance safety but also promote standardization, interoperability, and cross-border collaboration.

In contrast, developing countries face challenges in enacting and enforcing traceability regulations due to limited institutional capacity, technological infrastructure, and funding. As such, global efforts should focus on providing technical and financial assistance to these regions to ensure equitable access to secure pharmaceutical systems.

Strategic Benefits for Healthcare Logistics

The reviewed studies confirm that tracking and traceability systems deliver measurable improvements in supply chain visibility, responsiveness, and accountability. Enhanced tracking supports faster product recalls, reduces inventory waste, and ensures that genuine medications reach patients (World Health Organization, 2021). Moreover, these systems empower healthcare providers with real-time data for demand forecasting and stock optimization, leading to more efficient resource allocation.

Barriers and the Way Forward

Despite evident benefits, implementation challenges persist:

- Cost and Infrastructure: Many healthcare facilities, especially in rural areas, lack the infrastructure to support sophisticated tracking systems.
- Interoperability Issues: Different systems often operate in silos, hindering seamless data exchange across supply chain nodes.
- Stakeholder Alignment: Successful traceability requires cooperation among regulators, manufacturers, distributors, and healthcare providers, which is often lacking.

To address these challenges, the development of open standards, capacity-building initiatives, and regional collaboration platforms is essential. Furthermore, international bodies such as WHO and donor agencies should play an active role in supporting traceability adoption in underserved regions.

CONCLUSION

This study has reviewed and synthesized current global practices, technologies, and challenges related to pharmaceutical tracking and traceability systems. The findings highlight that the integration of technologies such as RFID, barcoding, and particularly blockchain, has significantly enhanced the security, transparency, and efficiency of pharmaceutical supply chains. These technologies enable real-time monitoring, reduce the risk of counterfeit drugs, and improve inventory management and recall processes.

However, the effectiveness of these systems is strongly influenced by the presence of clear regulatory frameworks. Countries with established policies—such as the United States and European Union—have demonstrated more successful implementation and adoption. Conversely, low- and middle-income countries continue to face substantial barriers, including high costs, limited digital infrastructure, and a lack of standardized systems.

The review also underscores the need for global collaboration and policy alignment to bridge implementation gaps and support developing countries in building reliable pharmaceutical logistics systems. Moving forward, governments, industry stakeholders, and international organizations must work together to create scalable, secure, and interoperable tracking solutions that can respond to global health needs and emergencies.

In conclusion, pharmaceutical traceability is not merely a technological upgrade but a strategic imperative for public health. Strengthening these systems will require not only innovation but also inclusive policies and sustained investments to ensure equitable access and improved outcomes across all regions.

BIBLIOGRAPHY

De Lima, C. A., de Oliveira, A. S., & Gomes, A. C. (2020). Blockchain-based traceability for supply chain management. Sensors, 20(14), 3821.

Kitchenham, B., & Charters, S. (2007). Guidelines for performing systematic literature reviews in software engineering. Keele University.

Mackey, T. K., & Nayyar, G. (2017). Digital health and counterfeit drugs. The Lancet Digital Health, 1(1), e6–e8.

https://doi.org/10.1016/S2589-7500(19)30003-4

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group. (2009). The PRISMA statement. PLoS Medicine, 6(7), e1000097.

Schoenberger, R., Copenhaver, D., & Tietz, M. (2019). Managing pharmaceutical supply chain risk. International Journal of Healthcare Management, 12(1), 1–8.

Tseng, J. H., Liao, Y. C., Chong, B., & Liao, S. W. (2018). Governance on the drug supply chain via Gcoin blockchain. International Journal of Environmental Research and Public Health, 15(6), 1055.

U.S. Food and Drug Administration. (2022). Drug Supply Chain Security Act (DSCSA). Retrieved from https://www.fda.gov/drugs

World Health Organization. (2021). Substandard and falsified medical products: Fact sheet.